

NDA 21891/S-31

SUPPLEMENT APPROVAL

Bayer Healthcare LLC Attention: Danielle Larino Associate Director, Regulatory Affairs 100 Bayer Boulevard PO Box 915 Whippany, NJ 07981-0915

Dear Ms. Larino:

Please refer to your supplemental new drug application (sNDA) dated and received December 12, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Claritin (loratadine) chewable tablets, 5 mg and 10 mg.

This "Prior Approval" supplemental new drug application provides for the following new proprietary name and associated labeling: Claritin Chewables (loratadine) tablets, 5 mg and 10 mg.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

LABELING

Submit final printed labeling (FPL) as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling. described in the table below and must be in the "Drug Facts" format (21 CFR 201.66), where applicable.

Also, submit FPL for the represented labels. Ensure that all changes approved for the submitted labels are incorporated onto the labels represented by the submitted labels described in the following table.

Labeling Submitted, 10 mg	Represents	Date
10-count carton (grape flavor)	N/A	04/01/2019
30-count carton (grape flavor)	N/A	04/01/2019
Labeling Submitted, 5 mg	Represents	Date
10-count carton (grape flavor)	20-, 30-, 40-, 50-count carton (grape flavor)	04/01/2019
10-count carton (bubblegum flavor)	20-, 30-, 40-count carton (bubblegum flavor)	04/01/2019
35-count carton (30 + 5 free, grape flavor)	25-count carton (grape flavor, 20 + 5 free)	04/01/2019
35-count carton (30 + 5 free, bubblegum flavor)	25-count carton (20 + 5 free, bubblegum flavor)	04/01/2019
40-count carton (30 + 10 free, grape flavor)	N/A	04/01/2019
40-count carton (30 + 10 free, bubblegum flavor)	N/A	04/01/2019
50-count backer card (grape flavor)	N/A	04/01/2019
50-count carton (professional sample bin, grape flavor)	N/A	04/01/2019
2-count pouch (grape flavor)	N/A	04/01/2019
60-count carton (grape flavor)	N/A	02/11/2019

The FPL should be submitted electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. For administrative purposes, designate this submission "Final Printed Labeling for approved NDA 21891/S-31." Approval of this submission by FDA is not required before the labeling is used.

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

¹ We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.² Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As.* In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sherry Stewart, Regulatory Project Manager, at (301) 796-9618.

Sincerely,

{See appended electronic signature page}

Theresa Michele, MD
Director
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURES:

Carton and Container Labeling

² http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

This is a representation of an electronic record that was signed
electronically. Following this are manifestations of any and all
electronic signatures for this electronic record.

/s/

THERESA M MICHELE 06/17/2019 05:21:35 PM